Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
NetherlandsIPO:
28 June 1996Website:
http://www.qiagen.comNext earnings report:
06 November 2024Last dividends:
30 January 2024Next dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:02:18 GMTAnalysts recommendations
Institutional Ownership
QGEN Latest News
QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat‑Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making
QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship // FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024 QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-target QIAstat-Dx Respiratory Panel Plus, clinicians can fine-tune their diagnostic approach for individual patients, promoting better diagnostic stewardship // FDA decision marks third positive U.S. regulatory outcome for QIAstat-Dx to date in 2024
Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024.
Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.
PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.
QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.
QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains // Collaboration ensures GEDmatch PRO development remains focused on the needs of forensic genealogists and investigators in the U.S. and other countries worldwide // Partnership builds on QIAGEN's leading global position in providing extensive portfolio for use in human identification and forensics QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains // Collaboration ensures GEDmatch PRO development remains focused on the needs of forensic genealogists and investigators in the U.S. and other countries worldwide // Partnership builds on QIAGEN's leading global position in providing extensive portfolio for use in human identification and forensics
QIAGEN launches 100 new assays for QIAcuity. The newly launched assays are now available through the company?
QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications // QIAcuity digital PCR enables accurate and sensitive detection of low-abundance pathogens, copy number alterations and identification of rare mutations // Portfolio expansion and partnerships support increased adoption of QIAcuity across multiple application areas QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications // QIAcuity digital PCR enables accurate and sensitive detection of low-abundance pathogens, copy number alterations and identification of rare mutations // Portfolio expansion and partnerships support increased adoption of QIAcuity across multiple application areas
What type of business is Qiagen NV?
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, such as STR assays for human ID, and assays for food contamination; PCR instruments include digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It also offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI; and with Bio-Manguinhos/Fiocruz to detect malaria and dengue. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
What sector is Qiagen NV in?
Qiagen NV is in the Healthcare sector
What industry is Qiagen NV in?
Qiagen NV is in the Diagnostics & Research industry
What country is Qiagen NV from?
Qiagen NV is headquartered in Netherlands
When did Qiagen NV go public?
Qiagen NV initial public offering (IPO) was on 28 June 1996
What is Qiagen NV website?
https://www.qiagen.com
Is Qiagen NV in the S&P 500?
No, Qiagen NV is not included in the S&P 500 index
Is Qiagen NV in the NASDAQ 100?
No, Qiagen NV is not included in the NASDAQ 100 index
Is Qiagen NV in the Dow Jones?
No, Qiagen NV is not included in the Dow Jones index
When was Qiagen NV the previous earnings report?
No data
When does Qiagen NV earnings report?
The next expected earnings date for Qiagen NV is 06 November 2024